CoChat

IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII

Open access
Matino, Davide, Gargaro, Marco, Santagostino, Elena, Di Minno, Matteo N.D., Castaman, Giancarlo, Morfini, Massimo, Rocino, Angiola, Mancuso, Maria E., Di Minno, Giovanni, Coppola, Antonio, Talesa, Vincenzo N., Volpi, Claudia, Vacca, Carmine, Orabona, Ciriana, Iannitti, Rossana, Mazzucconi, Maria G., Santoro, Cristina, Tosti, Antonella, Chiappalupi, Sara, Sorci, Guglielmo, Tagariello, Giuseppe, Belvini, Donata, Radossi, Paolo, Landolfi, Raffaele, Fuchs, Dietmar, Boon, Louis, Pirro, Matteo, Marchesini, Emanuela, Grohmann, Ursula, Puccetti, Paolo, Iorio, Alfonso, Fallarino, Francesca · 2015 · Journal of Clinical Investigation
Cited by 46

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The development of inhibitory antibodies to factor VIII (FVIII) is a major obstacle in using this clotting factor to treat individuals with hemophilia A. Patients with a congenital absence of FVIII do not develop central tolerance to FVIII, and therefore, any control of their FVIII-reactive lymphocytes relies upon peripheral tolerance mechanisms. Indoleamine 2,3-dioxygenase 1 (IDO1) is a key regulatory enzyme that supports Treg function and peripheral tolerance in adult life. Here, we investigated the association between IDO1 competence and inhibitor status by evaluating hemophilia A patients harboring F8-null mutations that were either inhibitor negative (n = 50) or positive (n = 50). We analyzed IDO1 induction, expression, and function for any relationship with inhibitor occurrence by multivariable logistic regression and determined that defective TLR9-mediated activation of IDO1 induction is associated with an inhibitor-positive status. Evaluation of experimental hemophilic mouse models with or without functional IDO1 revealed that tryptophan metabolites, which result from IDO1 activity, prevent generation of anti-FVIII antibodies. Moreover, treatment of hemophilic animals with a TLR9 agonist suppressed FVIII-specific B cells by a mechanism that involves IDO1-dependent induction of Tregs. Together, these findings indicate that strategies aimed at improving IDO1 function should be further explored for preventing or eradicating inhibitors to therapeutically administered FVIII protein.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci81859

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 46

Metadata

Authors
Matino, D., Gargaro, M., Santagostino, E., Di Minno, M. N. D., Castaman, G., Morfini, M., Rocino, A., Mancuso, M. E., Di Minno, G., Coppola, A., Talesa, V. N., Volpi, C., Vacca, C., Orabona, C., Iannitti, R., Mazzucconi, M. G., Santoro, C., Tosti, A., Chiappalupi, S., Sorci, G., Tagariello, G., Belvini, D., Radossi, P., Landolfi, R., Fuchs, D., Boon, L., Pirro, M., Marchesini, E., Grohmann, U., Puccetti, P., Iorio, A., & Fallarino, F.
Venue
Journal of Clinical Investigation
Published
2015-08-31
Volume
125
Issue
10
Pages
3766-3781
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2099259456
Cited by
46
References
5
FWCI
5.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.